Navigation Links
Sangart, Inc. Completes Series F Funding Round
Date:3/12/2009

SAN DIEGO, March 12 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen therapeutics, today announced the receipt of approximately $50 million in funding from existing investors. This investment results from the exercise of warrants issued by Sangart as part of a Series F financing round initiated in 2007. The most recent investment brings the total funding under the Series F round to approximately $100 million. Proceeds from this warrant exercise will be used to fund further clinical development of Sangart's MP4 oxygen therapeutic products.

"We are excited to see this continued support from our investors and believe it demonstrates the potential of our products," said Brian O'Callaghan, President and CEO of Sangart. "This funding contributes significantly to our efforts to further the clinical research and development of our MP4 oxygen therapeutic products."

About MP4 Oxygen Therapeutics

The MP4 molecule is the basis for Sangart's oxygen therapeutic product platform. The MP4 molecule is created using unique polyethylene glycol conjugation with human hemoglobin and was specifically designed to the optimal molecular size, viscosity, oxygen affinity and diffusion potential to target oxygen delivery to tissues at risk of oxygen deprivation based on experiments with artificial capillaries and in several different animal models. Extensive research and testing demonstrates that this approach optimizes oxygen delivery while minimizing the side effects that plagued earlier generation products.

About Sangart

Sangart, Inc. is a privately held biopharmaceutical company focused on being the global scientific, clinical and commercial leader in oxygen-therapeutic agents, providing innovative products to patients in need. Sangart was founded based on technologies developed during more than two decades of research into the mechanisms of oxygen transport by cell-free hemoglobin solutions at the Letterman Army Institute of Research and University of California at San Diego. The discoveries arising from this research on the effective action of oxygen therapeutics have been patented and published in numerous scientific articles and form the basis for Sangart's technologies.

To learn more about Sangart, please visit the company's website at www.sangart.com.

    Media Contact:
    Marissa Green
    Edelman Public Relations     Office: 323-202-1463
    Marissa.Green@edelman.com    Cell: 917-345-3684


'/>"/>
SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
2. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
3. Cardium Completes $3.5 Million Credit Facility
4. Proteon Therapeutics Completes $38M Equity Financing; Initiates Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients and Signs Option Agreement With Major Pharmaceutical Company
5. Enobia Completes Target Enrollment in Clinical Trial for Infantile Hypophosphatasia
6. CIRM Completes Briefing Visit to Stemedica Cell Technologies
7. INVO Bioscience Completes Reverse Merger
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
11. New Generation Biofuels Completes Construction of Baltimore Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... According to a new market research report "Oligonucleotide Synthesis Market ... (Research, PCR, Gene, DNA, NGS, Diagnostic, RNAI), End user (Academic, Pharmaceutical, ... is expected to reach USD 2.20 Billion by 2021 from USD ... forecast period. Continue Reading ... ...
(Date:12/8/2016)... ... 2016 , ... From wearable devices that can improve performance ... Thursday, December 15th a panel of entrepreneurs, innovators and a Philadelphia Eagles front ... Smart Talk session. Smart Talk will run from 8:30 – 10:30 a.m. at ...
(Date:12/8/2016)... ... December 08, 2016 , ... The ... — optogenetics — is key to exciting advances in the study and mapping ... light projected via free-space optics stimulates small, transparent organisms and excites neurons within ...
(Date:12/8/2016)... ... December 08, 2016 , ... KBioBox llc ... to client demand KbioBox developed a sophisticated “3 click” gene dditing off target ... from KBioBox’s new website, https://www.kbiobox.com/ and powered by the company’s ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Veridium , ... the appointment of new CEO James Stickland ... with decades of experience, has served in senior ... where he specialized in expanding a pipeline of ... portfolios. He most recently served as managing director ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/30/2016)... , Nov. 30, 2016  higi SH ... new partnership initiative targeting national brands, industry thought-leaders ... reward their respective audiences for taking steps to ... its inception in 2012, higi has built the ... impacting over 38 million people who have conducted ...
Breaking Biology News(10 mins):